Trial Profile
A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain Metastasis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Brain metastases; Triple negative breast cancer
- Focus Therapeutic Use
- 15 Aug 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2022.
- 27 Dec 2021 Planned primary completion date changed from 30 Sep 2021 to 1 Jun 2022.
- 15 Dec 2020 Status changed from recruiting to active, no longer recruiting.